Consensus recommendations for optimizing biomarker testing to identify and treat advanced EGFR-mutated non-small-cell lung cancer

The advent of personalized therapy for non-small-cell lung carcinoma (nsclc) has improved patient outcomes. Selection of appropriate targeted therapy for patients with nsclc now involves testing for multiple biomarkers, including EGFR. EGFR mutation status is required to optimally treat patients wit...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Curr Oncol
Main Authors: Cheema, P.K., Gomes, M., Banerji, S., Joubert, P., Leighl, N.B., Melosky, B., Sheffield, B.S., Stockley, T., Ionescu, D.N.
Formato: Artigo
Idioma:Inglês
Publicado em: Multimed Inc. 2020
Assuntos:
Practice Guideline
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7755440/
https://ncbi.nlm.nih.gov/pubmed/33380864
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.27.7297
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados